Compare Axon Enterprise Inc (AXON) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axon Enterprise Inc vs ResMed Inc. — how do they compare? Axon Enterprise Inc trades at $594.76 (market cap $51.69B), while ResMed Inc. trades at $225.94 (market cap $32.61B). The key difference: Axon Enterprise Inc is the larger of the two by market cap, and ResMed Inc. pays a 1.17% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.
| AXON | RMD | |
|---|---|---|
Market Cap | $51.69B | $32.61B |
Sector | Technology | Health |
52-Week High | $791.62 | $293.73 |
52-Week Low | $345.94 | $182.82 |
Enterprise Value | $52.83B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise trades at $595.63, showing slight consolidation after recent strength with a bullish technical outlook. The company delivered strong Q2 2026 results with 35% revenue growth and raised full-year guidance, though valuation metrics remain elevated with a P/E of 265. Analyst sentiment is overwhelmingly positive with 81% buy ratings and a $685 consensus target.
Axon's razor-and-blade model drives hardware adoption and high-margin software growth, supported by AI capabilities and $15.1B in future contracted bookings. Key risks include valuation concerns, gross margin pressure from service mix, and execution challenges in scaling new products. The stock offers growth exposure but requires monitoring of margin trends.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
